Skip to main content
. 2021 Jan 7;170:71–82. doi: 10.1016/j.addr.2021.01.001

Table 3.

Reported neutralizing antibody titers for a selection of COVID-19 vaccines that have been tested in Phase 1 and Phase 1-2 human clinical trials.

Vaccine candidate Category Doses Neutralizing AB titersa Ref.
ChAdOx1 nCoV-19 Vectored Vaccine 2 Ic50: 451b [174]
Ad26.COV2.S Vectored Vaccine 1 Ic50: 243c [175]
mRNA-1273 RNA 2 Ic50: 374d [176]
BNT162b2 RNA 2 Ic50: 363e [177]
NVX-CoV2373 Recombinant Protein 2 Ic99: 3,906f [6]
a

Highest reported value in the referenced publication.

b

50% neutralization titer, 5x109 viral particles, 42 days post first vaccination.

c

50% neutralization titer, 1x1011 viral particles, 29 days post first vaccination.

d

Ic50, 250 μg, 36 days post first vaccination.

e

50% neutralization titer, 20 μg RNA vaccine, 28 days post first vaccination.

f

Wild-type SARS-CoV-2 microneutralization, inhibitory concentration greater than 99% (MN IC>99%) titer response, 5 μg adjuvanted protein, 35 days post first vaccination.